B*CURED’s primary goal is to fund innovative brain cancer research to end brain cancer.
We invite clinical doctors and research scientists whose primary focus is brain cancer to apply for our grants. Clinical and translational projects with significant clinical promise will be considered. Both adult and pediatric brain cancer projects will be considered.
Since it’s establishment in 2008, B*CURED has funded 21 programs at prominent US hospitals and universities.
The 2017 grant program is now open. Please CLICK HERE for the 2017 application.
For further information, please see our FAQ 2017 or contact us at firstname.lastname@example.org.
B*CURED’S GRANTS TO DATE
Manish Aghi, MD, University of California, San Francisco “Defining Gene Expression Profiles of Tumor-Associated Neutrophils in Glioblastoma to Develop Novel Therapeutic Approaches (Immunotherapy)”
Justin Lathia, MD, Cleveland Clinic “Reversing Immune Cell Suppression in Glioblastoma by Targeting Myeloid-derived Suppressor Cells (Immunotherapy)”
Elias Sayour, MD, University of Florida, McKnight Brain Center “Host Immunomodulatory RNA-nanoparticles targeting malignant canine glioma (Immunotherapy)”
David J. Robbins, MD, University of Miami “Identification of Novel Inhibitors to Treat Childhood Brain Tumors” (Rare Deadly Childhood Cancer)
Markus Siegelin, MD, Columbia University “Induction of Synthetic Lethality in IDH1 Mutated Gliomas”
B*CURED – NREF Partnership Grantee:
James Purzner, MD, Stanford University “Exploring the Epigenetic Regulation of Neuronal Differentiation to Differentiate Medulloblatoma Cells (Pediatric Cancer)”
Thomas deRaedt, Brigham and Women’s Hospital (Harvard) “Developing a fast, powerful in vivo screening tool for cooperating drivers in GBM”
Sean Lawler, Brigham and Women’s Hospital (Harvard) “Development of novel brain penetrating, glioma-specific nanomedicines as brain cancer therapeutics”
Carl LeKaye, Memorial Sloan-Kettering Cancer Center “In vivo MR characterization of response to IDH1 R132H inhibition in preclinical glioma models”
Mariano Viapiano, Brigham and Women’s Hospital (Harvard) “Engineering a brain-penetrating reagent against the microenvironment of malignant brain tumors”
Dimitris Placantonakis, MD, PhD, NYU School of Medicine, “Role of GPR133 in Glioblastoma Stem Cell Biology”
Sunitha Thakur, PhD, Memorial Sloan-Kettering Cancer Center, “MRI Spectroscopy Quantification of the 2-Hydroxyglutarate (2HG) Oncometabolite in Mutant lsocitrate Dehydrogenase (IOH) Brain Glioma”
Brain Nahed, MD, Massachusetts General Hospital, “Identification and Analysis of Circulation Brain Tumor Cells” (See published work here).
Jennifer Yu, MD, PhD, Cleveland Clinic, “Hyperthermia Overcomes Radio Resistance of Glioblastoma Initiating Cells
Thomas Kaley, MD, PhD, Memorial Sloan-Kettering Cancer Center, “Tumor Treating Fields with Novo TTF for recurrent Atypical and Anaplastic Meningioma”
Jiangbing Zhou, Yale University Medical School, “Targeted delivery of combination therapy for GBM using multi-functional ultrasmall nanoparticles loaded with siRNAs”
Andrew Lassman, MD, New York Presbyterian/Columbia University Medical Center, “Pulsatile Kinase Inhibitor Therapy for Malignant Glioma: Proof of Concept Clinical Trial”
Antonio Omuro, MD, Memorial Sloan-Kettering Cancer Center, “Phase 1 Trial of 929097 in Combination with Standard Radiotherapy and Temozolomide for Newly Diagnosed Malignant Glioma: a Pharmacokinetic and Pharmacodynamic study”
William Curry, MD, Massachusetts General Hospital, “Host Antitumor Immunity in Glioma Patients Vaccinated with Autologous Irradiated Tumor Cells”
Ingo Mellinghoff, MD, Memorial Sloan-Kettering Cancer Center, “Development of Biomarkers to Evaluate Kinase Inhibitor Response in Glioma”